Tumor Evolution: A Problem of Histocompatibility

Natalie I Vokes; Eliezer M Van Allen

doi:10.1016/j.cell.2017.11.012

Tumor Evolution: A Problem of Histocompatibility

Cell. 2017 Nov 30;171(6):1252-1253. doi: 10.1016/j.cell.2017.11.012.

Authors

Natalie I Vokes¹, Eliezer M Van Allen²

Affiliations

¹ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
² Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA; Center for Cancer Precision Medicine, Dana-Farber Cancer Institute, Boston, MA, USA. Electronic address: eliezerm_vanallen@dfci.harvard.edu.

Abstract

In this issue of Cell, two articles show that tumor-specific changes in HLA-mediated antigen presentation affect tumor immunogenicity and may play a role in shaping cancer cell survival.

Publication types

Comment

MeSH terms

Alleles
Antigen Presentation*
Antigens, Neoplasm
Histocompatibility Antigens Class I / genetics
Humans
Lung Neoplasms*

Substances

Antigens, Neoplasm
Histocompatibility Antigens Class I

Grants and funding

T32 CA009172/CA/NCI NIH HHS/United States